Stroke is one of the leading causes of adult disability and the fourth leading cause of mortality in the US. Stroke disproportionately occurs among the elderly, where the disease is more likely to be fatal or lead to long-term supportive care. Animal models, where the ischemic insult can be controlled more precisely, also confirm that aged animals sustain more severe strokes as compared to young animals. Furthermore, the neuroprotection usually seen in younger females when compared to young males is not observed in older females. The preclinical literature thus provides a valuable resource for understanding why the aging brain is more susceptible to severe infarction. In this review, we discuss the hypothesis that stroke severity in the aging brain may be associated with reduced functional capacity of critical support cells. Specifically, we focus on astrocytes, that are critical for detoxification of the brain microenvironment and endothelial cells, which play a crucial role in maintaining the blood brain barrier. In view of the sex difference in stroke severity, this review also discusses studies of middle-aged acyclic females as well as the effects of the estrogen on astrocytes and endothelial cells.
Introduction
Stroke is the 4th leading cause of death and the leading nonmartial cause of disability. The prevalence of stroke in the 60-79 year old group is 6.2% for men and 6.9% for women, which practically doubles in the 80+ years age group, where the incidence is 13.9% for males and 13.8% of females (Go et al., 2013) , indicating that this disease disproportionately affects the elderly. Not surprisingly, the incidence of hypertension, a principal risk factor for stroke is also highly prevalent in this population estimated at 69.6% of all women aged 65-74, and 64.7% of all men aged 65-74 (Go et al., 2013) .
Besides an elevated risk for stroke, old age is also an adverse prognosticator of stroke outcomes (Jongbloed, 1986) , using several measures including survival, functional recovery, and hospitalization. In an early study of 415 patients with transient ischemic attack (TIAs), 1 year and 5 year survival was negatively correlated with advanced age (Howard et al., 1987) . A prospective analysis of 515 stroke patients (Copenhagen Stroke Study), showed that outcome measures such as the activities of daily living (measured by the Barthel Index [BI] ) were significantly worse in older patients, although neurological outcomes were not affected by age (Nakayama et al., 1994) , suggesting a poorer ability to compensate among this older population. Furthermore, hospitalization length was significantly increased in older patients (>65 years) with stroke (Qureshi et al., 2013) . Observational studies in university-hospital settings reported that age was a highly significant predictor of poor functional outcome (Knoflach et al., 2012; Denti et al., 2010; Abanto et al., 2013) . Moreover, a small study of centenarians also confirmed that strokes were much more severe in this population than in other age groups (Olsen and Andersen, 2013) . Morphologically, aging is associated with decreased salvage of penumbral tissue, and leptomeningeal collateral circulation is reduced in aging stroke patients and associated with a poorer outcome (Arsava et al., 2013) .
Because of longevity, projected stroke-related disability and institutionalization is likely to affect women more than men (Lai et al., 2005) . Although earlier studies indicated that the increased incidence of stroke in women did not occur until age 80, newer studies suggest that the risk for stroke in middle aged women doubles that of men (Towfighi et al., 2007) . Furthermore, women account for 60% of stroke-related deaths (Lloyd-Jones et al., 2010) , even after normalization for age. A Canadian stroke registry study reported that 10% of women stroke patients were discharged to long term care as compared to 5% men (Kapral et al., 2005) , despite the observation that stroke size tends not to be different in males and females (Silva et al., 2010) . Finally, 5-year stroke recurrence is 0197-0186 Ó 2013 The Authors. Published by Elsevier Ltd. http://dx.doi.org/10.1016/j.neuint.2013.06.013 disproportionately higher in females (20%) as compared to males (10%) in the 45-64 age range (Roger et al., 2011) . In the Danish National Registry analysis, women were reported to have more severe strokes than men although they exhibited a survival advantage compared to men, especially at advanced ages (Olsen and Andersen, 2010) .
Age differences in stroke outcomes in preclinical models tend to mirror the findings of the clinical studies. A comparison of young and aged male and female mice subject to a middle cerebral artery occlusion (MCAo) revealed that young females sustain a smaller infarct as compared to young males or aged female mice (Liu et al., 2009 ) although by 2 weeks, both young and aged groups were comparable (Manwani et al., 2011) . In a study of 10d, 63d and 180d old animals, functional recovery was most prominent in the neonate and was impaired in the older age groups, suggesting that stroke-related recovery is best in the immature brain (Yager et al., 2006) . Similarly, post stroke epilepsy, a common complication in this disease, was more common in older animals as compared to younger ones (Kelly et al., 2001) . At the cellular level, aged animals are able to mount a cytoprotective response to stroke but the timing of glial and endothelial proliferation is accelerated, resulting in rapid infarct development and poor prognosis in aged animals (Popa-Wagner et al., 2007) . Biomarkers for stroke injury also appear to be age dependent. Nitric oxide, for example, was reduced in plasma of aged stroke patients while it was elevated in younger and less severe cases, and IL-6 was elevated in aged patients with a poor outcome (Shakarishvili and Beridze, 2008) . Additionally, stroke therapies may also display age-dependent effectiveness. For example, the NOX2 inhibitor apocynin reduces infarct volume in young animals while increasing infarct volume and edema in older animals . Similarly, the plasminogen activator inhibitor type 1 derived peptide, EEIIMD, reduced infarct volume in both young and old animals but did not reduce edema in old animals ).
Sex differences in stroke outcome are also well recognized in preclinical models. Females have a smaller infarct and better cerebral blood flow than age-matched males both in normoglycemic (Alkayed et al., 1998) and diabetic (Toung et al., 2000) animals. However, although female mice sustain a much smaller infarct as compared to age matched males (Manwani et al., 2011) , aged females showed significantly more mortality and poorer stroke outcomes as compared to older males. The female advantage seen in young age demographics as well as animal models has led to the hypothesis that estrogen, the major ovarian hormone, may be protective for stroke. Using natural variations in circulating estrogen levels across the estrous cycle, Liao et al. (2001) showed that the extent of ischemic damage was inversely related to circulating levels of estrogen. In fact, replacement with 17b estradiol and its inactive stereoisomer 17a estradiol as well as the conjugate equine estrogen preparation (McCullough et al., 2001 ) all reduce infarct volume in female animals. Exogenous estrogen replacement is neuroprotective when given prior (Dubal et al., 1998) or subsequent to the injury Yang et al., 2003) .
However, hormone effects are more complicated in the context of aging. Hormone therapy at menopause is a specific concern for stroke outcomes since this middle aged demographic is at increased risk for stroke. Our studies have specifically addressed this reproductive transition phase by studying acyclic, middle-aged female animals (Johnson et al., 2006; Selvamani and Sohrabji, 2010a,b) . Reproductive senescent rats are characterized by reproductive criteria including multiple previous successful pregnancies, current reproductive failure, and constant diestrus (a low estrogen state) as determined by vaginal smears. Plasma levels of estradiol are low and FSH levels are elevated, consistent with a menopausal pattern. MCAo in this middle aged female results in a significantly larger infarct as compared to young females (Selvamani and Sohrabji, 2010a) , suggesting that the loss of ovarian hormones may accelerate age-related stroke severity. Furthermore, estrogen treatment to ovariectomized reproductive senescent females paradoxically increases infarct volume, indicating that the aging brain may be refractory to hormone mediated neuroprotection (Selvamani and Sohrabji, 2010a,b) . This was confirmed by another study where long term estrogen replacement to aged females also failed to improve stroke (Leon et al., 2012) .
While the specific cause for age-related severity in stroke outcomes is not clear, several theories abound. Stroke causes sprouting of axons and reorganization of connections in the peri-infarct area, which is associated with behavioral recovery. Sprouting is hindered in the aged stroke animals, and a recent study shows that the transcriptome of the sprouting neurons in aging animals differs considerably from the sprouting neurons in young animals . Genes families such as cytokines, chemokines, growth factors and axon guidance molecules were specifically affected with age, as well as genes associated with the Nogo receptor-1 complex, which is associated with inhibition of axonal sprouting in other injury models (Lee et al., 2004) .
While the phenotype of the aging neuron will critically impact stroke severity, neuronal survival will also be compromised by age-related changes in brain support cells. This review will specifically focus on the endothelium and astrocytes, their function in ischemic stroke, and the impact of age on their protective functions.
Endothelial cells
Endothelial cells are the principal component of the blood brain barrier and the building block of microvascular capillary networks. These cells play a central role in maintaining brain function and repair. Blood brain barrier: The blood brain barrier, which evolved to regulate the influx and efflux of cells, molecules and ions, consists of closely apposed endothelial cells, supported by astrocytic end feet and pericytes (Risau and Wolburg, 1990; Abbott et al., 2006; Kulik et al., 2008; Haseloff et al., 2005) . Among the many age-related changes in endothelial function, alterations in the blood brain barrier are most likely to elevate the risk for stroke and severity. Age-related changes in the microvasculature increases blood brain barrier permeability (Kalaria, 1999; Abbott, 2000; Farrall and Wardlaw, 2007; Grammas et al., 2011) although the reasons underlying this change are not known. In humans, normal aging is associated with increased blood brain barrier permeability and is further increased in patients with vascular dementia and Alzheimer's disease (Farrall and Wardlaw, 2007) . Blood brain barrier disruption enhances infiltration of serum proteins into brain parenchyma (Loftspring et al., 2006) and triggers an inflammatory response. Chief among the features that promote barrier function in cerebral endothelial cells are the presence of tight junctions between adjacent cells that effectively modulates the passage of ions and nutrients as well as acts as a gatekeeper to blood borne toxins (Brightman and Reese, 1969) . Junctional proteins, which include claudins, occludin and Junction Adhesion Molecules (JAMs), prevent transcellular transfer across the barrier. Claudin-5, which is preferentially found in brain endothelial cell membranes is crucial for maintaining barrier properties (Matter and Balda, 2003) , while deletion of claudin-5 in mice results in size-dependent disruption of the blood brain barrier (Nitta et al., 2003) . Following stroke, blood brain permeability is enhanced in older animals and tPA, the thrombolytic compound approved for stroke treatment, further increases barrier permeability concomitant with activation of occludin and claudin-5 (Kaur et al., 2011) .
Age also affects the permeability and efflux capacity of the barrier. In a cortical contusion injury, barrier permeability was greater in aged animals as compared to young animals and was accompanied by a reduction of claudin-5 but not occludin (Lee et al., 2012a) . However, no differences were found in the mRNA levels of claudin, occludin or ZO1 between young, middle aged and old mice, nor were there changes in the penetration of the anti-muscarinic drug trospium chloride at any of these ages (Kranz et al., 2013) . Aging does impact the function of P-glycoprotein (Prg), a key efflux transporter, however recent studies show that this may be restricted to males (van Assema et al., 2012) .
Consistent with the high demand for active transport in these cells, barrier-forming endothelial cells contain significantly greater mitochondrial content than non-barrier forming endothelial cells (Oldendorf et al., 1977) . Elevated mitochondrial content is indicative of transformation to barrier-type endothelial cells (Hayashi et al., 1997) and is decreased in diseases such as multiple sclerosis where the BBB permeability is increased (Claudio et al., 1989) . In both rats and monkey, mitochondrial content of endothelial cells is reduced with age (Burns et al., 1981) , while mitochondrial DNA mutations increase during aging and in age-related neurologic conditions such as Alzheimer's disease (Muller et al., 2010) .
Mitochondrial oxidative stress is a leading cause of vascular/ endothelial dysfunction in aging population. Brain endothelial cells act as both source and target for reactive oxygen species (Strasser et al., 1997; Haorah et al., 2007) . With advancing age, the synthesis of reactive oxygen species increases in endothelial cells (reviewed in (Csiszar et al., 2008; Ungvari et al., 2007) ), resulting in inactivation of the vasodilator nitric oxide (NO), and, consequently, reduced vasodilator capacity and perfusion of tissues (Csiszar et al., 2005) . Aging also increases iNOS in microvessels of hypertensive subjects (Smith et al., 2011) and aging male rats (Cernadas et al., 1998) , often considered a compensation for reduced NO levels. Age-related elevation of oxidative stress is accompanied by a chronic low-grade inflammatory phenotype marked by NF-kB activation (Ungvari et al., 2007) . Furthermore, age-associated mitochondrial oxidative stress promotes mitochondrial protein oxidation and mitochondrial DNA mutations [reviewed in (Dai and Rabinovitch, 2009)] , and is speculated to cause endothelial apoptosis (Yamamori et al., 2005; Lopez-Lopez et al., 2007) . Decreased density of cerebral arterioles in aging (Sonntag et al., 1997 ) is consistent with the idea of vascular deterioration, although it remains to be determined if this is directly related to endothelial oxidative stress. The role of oxidative stress and stroke has been well documented (reviewed in Olmez and Ozyurt (2012) ), however, there is limited information on effects of midlife events such as menopause on brain endothelium in the context of stroke. Estrogen treatment to ovariectomized animals has been shown to reduce oxidative stress in the hippocampus following ischemia (Zhang et al., 2009) , suggesting that the loss of ovarian hormones at menopause may influence stroke severity through increased oxidative stress. Evidence from in vitro studies (reviewed later) suggests that the endothelium is a potential target of estrogen action.
Endothelial cells and cerebral blood flow
Reduced cerebral blood flow with age has also been reported for rats (Ohata et al., 1981; Berman et al., 1988) and monkeys (Noda et al., 2002) and humans (Schultz et al., 1999) . Interestingly, cerebral blood flow reduction may occur as early as midlife (50 years) (Schultz et al., 1999) , consistent with elevated stroke risk during this time frame. Through production of vasodilatory and vasoconstrictive molecules, cerebrovascular endothelium plays an important role in regulating blood flow, which is also critical during reperfusion following stroke (Gursoy-Ozdemir et al., 2012). The discovery of nitric oxide a potent endothelial-derived vasodilatory factor (Ignarro et al., 1987) and EDHF (Bryan et al., 2005) , as well as the vasoconstrictor endothelin-1 (Yanagisawa et al., 1988) together constitute the most well-studied endothelial secretions. Pathologic conditions that alter these effectors, especially the nitric oxide system, impair vascular tone. The NO system is the target of intensive study for the design of new drugs for cerebrovascular disease. One of the most prominent reasons for NO insufficiency is age, due in part to the age-related reduction of nitric oxide synthase (Pie et al., 2002) and an age-related increase in arginase, that degrades the natural substrate for NOS (Berkowitz et al., 2003) . In fact age is the most significant predictor of endothelial-dependent vasodilation (Gerhard et al., 1996) , although endothelial-independent vasodilation is not affected by age. In coronary circulation, endothelial-derived NO decreases dramatically in 70-80 years old patients as compared to 20 years old patients (Egashira et al., 1993) , consistent with the observation that cerebral blood flow is negatively correlated with age in a study of 20-100 years old individuals (Tachibana et al., 1984) . However, evidence from brachial artery derived endothelium suggests that the age-related decline in endothelial-dependent vasodilation in this vessel is inversely correlated with ET-1 expression in brachial-derived endothelial cells, while eNOS was not significantly different with age. Furthermore, the ET-1 receptor antagonist BQ-123 restored 60% of the agerelated impairment in endothelial-dependent dilation, linking the age response to elevation of vasoconstrictive, rather than vasodilatory factors (Donato et al., 2009) . While this issue remains to be explored in cerebral vessels, it is also worth considering that age may impair the response to these compounds. For example, adenosine administration induced greater vasodilation in young animals as compared to older animals (Jiang et al., 1992) , while intravascular serotonin exacerbates vasoconstriction in older animals (Hajdu et al., 1993) . Thus, the aging brain is more likely to be subject to hypoperfusion and, potentially, greater neuronal damage.
While little information is available on the influence of midlife events such as menopause on endothelial dysfunction and its role in cerebral blood flow, reports suggest that estrogen affects the NO system by increasing the expression of eNOS in cerebral arteries (Geary et al., 1998) and cerebral microvessels (McNeill et al., 1999) and activates the PI3K-Akt-NO signaling cascade in cerebral microvessels (Stirone et al., 2005) , indicating that the loss of this ovarian hormone at midlife will significantly impact cerebral vascular tone. However, recent studies using a microfluidics approach cautions conclusions drawn from estrogens effects on a single cell type taken in isolation. Thus while estradiol increases NO in endothelial cells, passaging erythrocytes through chambers containing endothelial cells significantly reduced NO synthesis by estradiol, possibly due to estradiol-mediated decreases in ATP from erythrocytes (Letourneau et al., 2010) . Moreover, even among young animals where estrogen treatment usually results in stroke neuroprotection, it is not usually thought to occur via alterations in cerebral blood flow (Rusa et al., 1999; Carswell et al., 2000) .
Ovarian hormone effects on barrier function: While there is clear evidence of age-associated disruption of blood brain barrier, alterations in barrier function due to menopause or reproductive senescence are relatively understudied. Menopause or reproductive senescence is associated with steep decline in ovarian hormones, and will likely impact barrier and endothelial function due to the known role of estrogen on this cell type. Experimental studies evaluating the influence of estrogen on blood brain barrier permeability generally indicate a protective function. Specifically, 17b-estradiol reduces barrier permeability following injury in young female rodents , increases glucose uptake and transport (Bishop and Simpkins, 1995; Shi et al., 1997) , reduces ischemic- (Chi et al., 2002 (Chi et al., , 2005 and VEGF-induced (Chi et al., 2004 ) leakiness of the blood-brain barrier in the cortex (Chi et al., 2002) , and protects neurons from 3NP toxicity, in vivo (Nishino et al., 1998) and in vitro (Mogami et al., 2002) . 17b-estradiol also reduces edema in an experimental stroke model by reducing the activity (O'Donnell et al., 2006) and abundance (Chang et al., 2008) of the Na-K-Cl cotransporter. Oral conjugate estrogens also reduce vascular lesions and leukocyte permeability caused by A-beta 40 and A beta-42 infusions (Rhodin et al., 2003) . However, estrogen acts synergistically with myelin basic protein to cause mast cell infiltration into the brain parenchyma (Theoharides et al., 1993) and the synthetic estrogen ethinyl estradiol is shown to increase the endothelial permeability to albumin (Gammal and Zuk, 1980) .
Most of these studies assess the effects of estrogen in ovariectomized young female animals, which models the surgical menopause and may not completely recapitulate the natural menopause. In a rodent model of reproductive senescence, we find that the effects of estrogen are not always neuroprotective (Sohrabji, 2005) . Reproductive aging is associated with increased permeability of the blood brain barrier in the hippocampus and olfactory bulb as compared to normally cycling young females (Bake and Sohrabji, 2004) . At the molecular/cellular level, this is accompanied by increased perivascular IgG expression in hippocampus, a commonly used marker to assess barrier integrity in aging and disease. Furthermore, constitutive expression of claudin-5 and occludin were not altered by age, however junctional localization of these proteins, which is critical to their barrier function was reduced in cerebral microvessels from middle aged reproductive senescent females (Bake et al., 2009 ). In fact, cerebral microvessels from a small sample of pre and post-menopausal women also confirmed this reproductive age-related loss of junctional localization (Bake et al., 2009) . Disrupted tight junctions are also seen in aging female hamsters (Gerrits et al., 2010) , although this is uncoupled from reproductive senescence.
Endothelial progenitor cells
Endothelial progenitor cells (EPCs) are immature endothelial cells found in peripheral circulation (Asahara et al., 1997) that are capable of repairing damaged endothelium during injury such as cardiac infarction and stroke. EPCs are also thought to be a surrogate or prognostic marker for endothelial dysfunction or vascular diseases. Lower levels of circulating EPCs are positively correlated with increases in age-related white matter lesions (Jickling et al., 2009 ) and increased cardiovascular disease and reduced vascular function (Hill et al., 2003; Schmidt-Lucke et al., 2005; Paul et al., 2007) . Conversely, CD34 EPC treatment also promotes angiogenesis, neurogenesis and better behavioral outcome in a stroke model (Uemura et al., 2012) . EPC are presumed to improve stroke outcomes due to upregulation of trophic factors (Chopp and Li, 2002) , and their ability to promote angiogenesis or vasculogenesis (Chu et al., 2008) . Thus conditions and disease that affect EPC expression may also impair stroke recovery. For example, the proportion and function of EPCs is affected by diabetes (Chen et al., 2011) , a major risk factor for cardiovascular and cerebrovascular diseases, while the cholesterol-reducing drug statins increases EPC's during the acute phase of ischemic stroke (Sobrino et al., 2012) . Age-related changes in EPC levels have not been studied extensively, but evidence indicates that although age does not affect the number of EPC's, their ability to migrate, proliferate and survive are significantly lowered in older subjects (61 y/o) as compared to young subjects (25y/o) (Heiss et al., 2005) , while the atheroprotective properties of EPC are reduced in aging mice (Rauscher et al., 2003) . In a cardiac injury model, EPCs from young mice were able to promote cardiac angiogenesis in older mice, while EPCs from older donors did not (Edelberg et al., 2002) . Thus an important issue for further study is to determine whether the intrinsic capacity of EPCs is altered with age, or whether the aging environment impedes EPC function.
Growth factors are critical for mobilizing EPCs from bone marrow to ischemic tissue and age-related decreases in SDF-1 and VEGF as well deficient HIF-1 signaling have been shown to impair EPC trafficking to ischemic sites (Chang et al., 2007) . Age-related changes in matrix molecules such as heparin sulfate also affect migratory function of EPCs (Williamson et al., 2012) . Furthermore, the antioxidant capacity of EPCs is also impaired with age. Specifically, levels and activity of the antioxidant enzyme glutathione peroxidase-1 are much lower in EPCs derived from old subjects (He et al., 2009) and are more susceptible to oxidative stress-induced apoptosis.
Reproductive hormones also influence EPC function. Estrogen and progesterone have been shown to improve EPC proliferation in blood during the menstrual cycle (Matsubara and Matsubara, 2012) and EPC-mediated postnatal vasculogenesis (Masuda et al., 2007) . Estrogen promotes EPC-mediated reendothelialization through nitric oxide following arterial injury in mice (Iwakura et al., 2003) and improves EPC-mediated neovascularization in a hind-limb ischemic model (Ruifrok et al., 2009) . At postmenopause, where estrogen levels are low, circulating EPC levels were significantly reduced as compared to pre-menopausal women (Bulut et al., 2007) . Similarly, EPCs are reduced in peripheral blood and bone marrow of ovariectomized mice, which can be prevented with estrogen treatment (Strehlow et al., 2003) . Furthermore, estrogen reduces cell senescence through telomerase activity (Imanishi et al., 2005) . Decline of ovarian hormones at menopause is thus likely to impact EPC function and subsequent recovery from cardiac and cerebrovascular disease.
Aging and angiogenesis
Angiogenesis or formation of new vessels is an adaptative response to ischemic injury (del Zoppo and Milner, 2006; Sonntag et al., 2007) . Hypoxia is a critical component of angiogenesis (Kanaan et al., 2006) and hypoxia induced upregulation of HIF-1 and VEGF promotes endothelial cell growth (Pugh and Ratcliffe, 2003) and ischemia induced angiogenesis (Greenberg, 1998) . Post-stroke angiogenesis is closely associated with neurogenesis (Zhang et al., 2002 (Zhang et al., , 2004 Chopp et al., 2007; Arai et al., 2011) , such that the angiogenic niche promotes neurogenesis (Palmer et al., 2000) . Neurons and astrocytes within the neurovascular unit also secrete trophic factors such as IGF-1 , VEGF (Ferrara et al., 2003) , and PDGF-b (Marti et al., 2000; Jin et al., 2002; Beck and Plate, 2009) to induce angiogenesis, which in turn enhances proliferation and differentiation of neuronal precursor cells to promote neurogenesis (Sun et al., 2003) . Co-cultures of rat brain endothelial cells with subventricular zone neural progenitor cells also provides indirect evidence that angiogenesis is coupled to neurogenesis (Teng et al., 2008) and is required for brain recovery after stroke (Xiong et al., 2010) . Thus reduced functional capacity of endothelial cells with age will not only affect vascular repair but also neurogenesis.
Few studies have addressed the role of aging and angiogenesis in the stroke brain, and the results are equivocal. Aged male F344 rats show significant decrease in capillary angiogenesis compared to young animals following hypoxia (Ingraham et al., 2008) , while in mice, both young and aged animals display similar microvessel densities 2-3 weeks after hypoxia, although hypoxia-induced upregulation of HIF-1a and Ang-2 was significantly reduced in the aged mice (Benderro and Lamanna, 2011) . Aging also impairs the angiogenic potential of senescent human umbilical vein endothelial cells (Garfinkel et al., 1996) , which is associated with reduced VEGF levels (Rivard et al., 1999 ). An experimental approach to replenish VEGF levels in aging mice, however, showed poor angiogenic response suggesting permanent change in VEGF activated downstream signaling pathways (Gao et al., 2009 ). Although HIF-1 activation is a primary step in angiogenesis, PPAR-gamma coactivator 1-alpha is also capable of inducing angiogenesis in aged F344 rats (Ndubuizu et al., 2010) . Using gene expression at the neurovascular unit as a marker for angiogenic capacity, resting gene expression was lower in aging animals, and the angiogenic response to hypoxia was also weaker in older animals (Murugesan et al., 2012) . Estrogen promotes angiogenesis in many vascular beds, and has also been shown to decrease free radical production, increase cell survival, and stimulate angiogenesis in cerebral endothelial cells (Krause et al., 2006) . However much less is known about the effects of estrogen on stroke-induced angiogenesis. In a study examining the effect of estrogen on angiogenesis and stroke, estrogen treatment increased Ang-1 and microvessel density prior to stroke (Ardelt et al., 2005) and increased microvessel density in the peri-infarct area at 10 days, but not 1 day, post stroke (Ardelt et al., 2007) .
Pericytes
Pericytes ensheath the capillary endothelial cells in the neurovascular unit (Shepro and Morel, 1993; Armulik et al., 2005) and play an important role in microcirculation (Hamilton et al., 2010) and angiogenesis (Gerhardt and Betsholtz, 2003) . Omission of pericytes in the neurovascular unit using a PDGFRb deletion mice showed impaired brain microcirculation and increased permeability to TMR-conjugated dextran (40Kd) (Bell et al., 2010) . Age-related neurodegeneration in this model was preceded by degenerative changes in microvessels, underscoring the importance of this cell type to brain microvessel health. In an in vitro BBB model, astrocytes and pericytes responded to hypoxia causing endothelial cell death but pericytes were able to maintain the barrier function better than astrocytes under prolonged oxygen deprivation (Al Ahmad et al., 2011) . In reproductive senescent female hamsters, vascular changes in endothelial cells and tight junctions were paralleled by pericyte degeneration and thickening of the basement membrane (Gerrits et al., 2010) . Age and hormone related changes in this cell type thus represent another important but understudied area that will impact stroke outcomes.
Astrocytes an active partner in brain dynamics
Originally described as merely a structural component of the brain (see review Allen and Barres (2009) , Volterra and Meldolesi (2005) , Dermietzel and Spray (1998) ) our understanding and the importance of astrocytes has advanced dramatically. Astrocytes play a prominent role in regulation of synaptic activity (Ullian et al., 2001; Ventura and Harris, 1999; Di Castro et al., 2011) ; extracellular matrix secretion (Wujek and Akeson, 1987; Liesi and Silver, 1988 ), blood-brain barrier integrity (Janzer and Raff, 1987; Kim et al., 2006 recent review) , neurovascular coupling (Zonta et al., 2003; Takano et al., 2006) and the inflammatory response (Fontana et al., 1982; Robbins et al., 1987) . Following brain injury astrocytes become reactive with increased expression of glial fibrillary acidic protein (GFAP) (Petito et al., 1990; Singh and Mathew, 1989; Ordy et al., 1993; Takamiya et al., 1988) . Astrocytes offer trophic support through secretion and/or expression of several soluble factors to include the neurotrophins (Lu et al., 1991; Yamakuni et al., 1987; Schwartz and Nishiyama, 1994; Riley et al., 2004) growth factors (Garcia-Estrada et al., 1992; Ridet et al., 1997; Banner et al., 1997; Zhang et al., 2006) or by regulating local glutamate concentrations (Schousboe et al., 1977) . Astrocytes are also a source for inflammatory cytokines/chemokines (Lau and Yu, 2001; Ridet et al., 1997; Ransohoff et al., 1993; Kim et al., 1995) which can potentially support or potentiate the injury response. The ability of astrocytes to offer either trophic support or exacerbate the injury is dependent on several factors including the extent of injury, age, hormonal status and any underlying pathology. In this section, the influence of aging, hormonal status, and sex-differences on astrocytes will be explored.
The aging astrocyte
The aging brain shows distinct changes in astrocyte morphology (Vaughan and Peters, 1974) , GFAP expression (Kohama et al., 1995; Mandybur et al., 1989; Rozovsky et al., 1998; Nichols et al., 1993) and astrocyte numbers (Mouton et al., 2002; Hansen et al., 1987) . Thus, astrocytes change over the lifetime and in the context of neuroinflammation, this aging process may be detrimental to astrocyte function. As earlier reports show, aging alone increases GFAP expression, however, increased astrocyte reactivity also occurs following injury (Badan et al., 2003; Gordon et al., 1997; Baldwin and Scheff, 1996; Topp et al., 1989) or chronic neurodegeneration (Vijayan et al., 1991) . Further, aging accelerates injury-induced astrocyte reactivity (Badan et al., 2003; Popa-Wagner et al., 2007; Gordon et al., 1997) . Following focal ischemia this exaggerated glial response coincides with accelerated glial scar formation (Badan et al., 2003) . In addition, matrix remodeling through reduced expression of astrocyte-derived SC1, an extracellular matrix-associated glycoprotein, may be impaired in aged rats following focal ischemia (Lively et al., 2011) .
Moreover, neurogenesis, a potential endogenous repair mechanism following brain injury may also suffer in part due to reduced astrocyte function with age. Decreased secretion of Wnt3, a protein involved in neural stem cell differentiation, from astrocytes resulted in impairments in hippocampal neurogenesis in aged (9 mo.) mice as compared to young (3 mo.) mice (Okamoto et al., 2011; Miranda et al., 2012) . Reductions in astrocyte-derived growth factors and their receptors such as insulin-like growth factor 1 (IGF-1) (Duenas et al., 1994; Lewis et al., 2012) , fibroblast growth factor receptor 2 (FGFR-2) (Chadashvili and Peterson, 2006) and vascular endothelial growth factor (VEGF) (Bernal and Peterson, 2011) may also contribute to reduced adult neurogenesis.
In vitro studies also show similar age-related dysregulation in astrocytes. Ex vivo cultures of astrocytes collected from the olfactory bulb of middle-aged female rats show increased stress fiber formation, reduced laminin deposition, increased BDNF expression and reduced TrkB expression compared to young astrocytes (Lewis et al., 2008a ) and more importantly, aged astrocytes show an impairment in their ability to promote neuronal differentiation of neural progenitor cells (Lewis et al., 2008a) . Moreover, reduced glutamate uptake has been reported in ex vivo adult, ischemiaactivated primary astrocyte cultures collected from 12 mo. old females that had been subjected to focal ischemia as compared to astrocytes collected from similarly-treated young adults (Lewis et al., 2012) . Given that aged rats show increased infarct size (Popa-Wagner et al., 2007; Selvamani and Sohrabji, 2010a) , impairments in glutamate clearance and metabolic dysregulation observed in the aging astrocyte likely leads to a more toxic microenvironment in the older brain.
Effects of sex hormones on astrocyte function
The sex (or gonadal) hormones androgen, estrogen and progesterone and their metabolites play a significant role in regulating astrocyte activity. Astrocyte morphology is altered by estradiol (Amateau and McCarthy, 2002; Garcia-Segura et al., 1989) and testosterone (Amateau and McCarthy, 2002) and GFAP expression is enhanced Satriotomo et al., 2004) or decreased in the presence of sex steroids depending on the treatment paradigm, region of interest and whether male or females animals were used. Moreover, sex hormones increase expression of astrocyte-derived growth factors (Platania et al., 2005; Galbiati et al., 2003) and regulate the glial glutamate transporters (Pawlak et al., 2005) .
Given the effects these hormones have in the uninjured brain, it is not surprising that they regulate astrocyte function following injury. Several in vivo studies point to an attenuation of reactive astrogliosis with hormone treatment. In gonadectomized male rats, injury-induced reactive astrogliosis is attenuated following replacement with estrogen, testosterone (Barreto et al., 2007; Garcia-Estrada et al., 1993; Day et al., 1993) , dihyrotestosterone progesterone as well as the neurosteroids dehydroepiandrosterone, pregnenolone and pregnenolone sulfate (Garcia-Estrada et al., 1999) . Estradiol was effective in reducing gliosis in male mice following MPTP treatment, an injury model for Parkinson's disease (Tripanichkul et al., 2006) . In addition, progesterone, estradiol (Garcia-Estrada et al., 1993) and the selective estrogen modulators (SERMS) raloxifene and tamoxifen (Barreto et al., 2009 ) reduced reactive gliosis in females. Following spinal cord injury, progesterone reduced proliferation and activation of astrocytes and microglia in male rats and increased OPC maturation suggesting a role for progesterone in reducing reactive gliosis and promoting myelin repair (Labombarda et al., 2011) and in juvenile mice estrogen ameliorated the inflammatory response through regulation of NF-jB in microglia and astrocytes following a manganese-induced injury (Moreno et al., 2011) . The estrogenmediated attenuation of astrogliosis following injury may be driven in part by the endocannabinoid signaling system as estrogen was ineffective in modulating the density and number of reactive astrocytes in male rats when antagonists to the cannabinoid receptors CB1 or CB2 were used (Lopez Rodriguez et al., 2011) . Although not in the context of injury, ovariectomized females given a single injection of testosterone propionate led to reduced GFAP expression (Garcia-Segura et al., 1988) . Estrogen however did not reduce astrocyte accumulation in mice following cuprizone-induced demyelination in the corpus callosum but did reduce oligodendrocyte loss and delayed microglial accumulation (Taylor et al., 2010) .
Studies also suggest neuroprotective interventions of sex hormones in vitro. In mixed-sex astrocyte primary cultures, up-regulation of aquaporin-4 (AQP4), an astrocyte-specific water channel was enhanced by testosterone but not 17b-estradiol after a 6 h treatment (Gu et al., 2003) . Increased AQP4 expression is linked to increased brain edema and astrocyte swelling but in this study although increased AQP4 expression increased there was a concomitant decrease in astrocyte osmotic fragility following testosterone treatment suggesting a neuroprotective role (Gu et al., 2003) . In the context of in vitro focal ischemia models, estradiol application to mixed-sex astrocyte cultures reduced astrocyte swelling following arginine vasopressin (AVP) treatment and hypoxia but was ineffective following aglycemia or oxygen-glucosedeprivation (OGD) (Rutkowsky et al., 2011) . Interestingly, here estradiol reduced expression of AQP4 after 7 day but not at acute (2-3 h) time points (Rutkowsky et al., 2011) . Thus it is possible AQP4 expression may have been modulated by 17b-estradiol in the Gu et al. (2003) study had the treatment time been extended. Cellular volume regulation has also been studied in female cortical astrocyte cultures. In testosterone treated cultures, cell volume regulation was normal while cells treated with estradiol or progesterone showed irregular volume regulation (Fraser and Swanson, 1994) suggesting that females may be more at risk for brain edema. Estradiol has also been shown to attenuate astrocyte-derived release of nuclear transcription factor NF-jB (Dodel et al., 1999) , cytosolic Ca 2+ (Arnold, 2005) , interleukin(IL)-1b, tumor necrosis factor (TNF)-a and matrix metalloproteinase-9 (Lewis et al., 2008b) in inflammatory injury models.
Sex hormones also act on astrocytes to up-regulate growth factors, genes and proteins that result in neuroprotective effects following injury. In spinal cord injury models, 17b-estradiol increases protein expression of the glutamate transporter-1 (GLT-1) in spinal cord astrocytes which in turn modulates the expression of the potassium channel Kir4.1 in astrocytes thereby regulating both local glutamate and potassium concentrations . In addition, manganese-induced impairments in the GLT-1 transporter, and subsequently glutamate uptake, are reversed in cortical astrocyte cultures by both 17b-estradiol and tamoxifen via increased expression of transforming growth factor alpha (TGFa) (Lee et al., 2012b) . In experimental autoimmune encephalomyelitis (EAE) the neuroprotective effects of estrogen treatment are due to signaling through estrogen receptor alpha (ERa) (Polanczyk et al., 2003; Morales et al., 2006 ) specifically on astrocytes (Spence et al., 2011) . Deletion of ERa in astrocytes but not neurons blocked the neuroprotective effects of systemic estrogen treatment. Severe clinical disease and an increased inflammatory response were observed in estrogen-treated mice lacking ERa in astrocytes as compared to mice lacking ERa in neurons (Spence et al., 2011) . Interestingly, the neuroprotective interventions by sex hormones may originate from the astrocyte itself or may result from paracrine signaling. Aromatase expression, a key enzyme in estrogen biosynthesis, is enhanced following a sub-lethal pressure increase in astrocyte cultures (Gatson et al., 2011) while estrogen treatment to astrocytes inhibits the steroid hydroxylase CYP7B1 which is responsible for metabolizing dehydroepiandrosterone (DHEA) an important precursor for both estrogen and testosterone (Fex Svenningsen et al., 2011) . Taken together these data suggest that sex hormones play a supportive role in astrocyte function, and further support the hypothesis that the loss of ovarian hormones at menopause may accelerate stroke severity in this population.
Sex differences and astrocytes
As discussed above, in animal models both male and female rodents respond to injury with increased GFAP expression and both respond well to hormonal manipulation. Several studies in rodents have examined sex differences in the context of injury, and show differences in astrocyte proliferation , astrocyte reactivity (Barna et al., 1996; Cordeau et al., 2008) and astrocyte survival (Nishino et al., 1998) , however, the results are divergent and the role of astrocytes is difficult to interpret.
In vitro mechanistic approaches have yielded more interpretable results. In neonatal primary astrocyte cultures derived from male pups, androgenized female pups or vehicle-treated pups, cytokine expression was increased by LPS treatment in male or androgenized female cultures as compared to intact females (Santos-Galindo et al., 2011) . Neonatal mesensephalic astrocytes collected from male mice treated with MPTP, a compound used to mimic Parkinson's disease, also showed an increased inflammatory profile and increased cell death as compared to similarly treated female astrocyte cultures (Sundar Boyalla et al., 2011) . Astrocytes derived from females but not males cleared significantly more glutamate through the GLAST transporter and motor neurons seeded onto female astrocytes were less susceptible to excess glutamate in the cultures (Morizawa et al., 2012) . Following OGD or oxidant cell death induced by H 2 O 2 , neonatal male primary astrocyte cultures were more susceptible to cell death as compared to age-matched female primary astrocyte cultures (Liu et al., 2007) . However, increased cell death was noted in female astrocyte cultures when additional inflammatory mediators such as IL-1b or TNF-a were combined with OGD (Liu et al., 2007 ). This sex difference may be due to higher aromatase expression in female astrocytes as compared to male astrocytes (Liu et al., 2007) . Recent data using adult ischemia-activated cortical astrocytes showed that astrocytes derived from aged females showed impairments in glutamate clearance as compared to young female astrocyte cultures, however these same impairments were not observed in age-matched male astrocyte cultures (Lewis et al., 2012) . In general, it appears that astrocytes derived from females are better able to handle insults however this is not true for all injury models and is likely brain region dependent.
Summary and conclusion
Endothelial cells and astrocytes play a key role in the pathophysiology of stroke. Endothelial cells act as a source and target of neurotoxic substances in an ischemic environment, and play a cardinal role in angiogenic repair, which is coupled to neurogenesis after stroke. Astrocytes also mediate the dynamic brain response to injury, by providing trophic support to neurons in the presence and absence of injury in part through regulation by sex hormones. Aging, however, can lead to astrocyte and endothelial dysregulation ultimately resulting in a toxic cellular environment and potentially increased neuronal loss following injury. The functional and anatomical interaction of endothelial cells and astrocytes is crucial in the case of the blood brain barrier. The blood brain barrier is severely impacted by ischemic stroke and an important, yet understudied, issue is how the aging blood brain barrier will impact neuronal survival in the ischemic brain and, reciprocally, how stroke affects the aging blood brain barrier.
Despite the large amount of data now available on endothelial and astrocyte function in stroke, there is little known about the function of these cells under conditions that impact stroke severity. Thus, there is an urgent need for animal models that match or duplicate the demographics most likely to have strokes or have more severe strokes. Besides aging models, such studies need to include other co-morbid conditions such as hypertension, highfat diet, hyperglycemia and other dietary deficiencies. From the prevailing studies, it is clear that older animals sustain more severe outcomes following stroke, which supports the use of these models in more granular analysis of the cellular and molecular changes that underlie these severe stroke effects. Similarly, dietary issue such as vitamin D deficiency (Balden et al., 2012) , high-fat diet (Li et al., 2013) , hypertension (Carswell et al., 2004) have all been successfully duplicated in animal models in the context of stroke, and should be further employed to understand the how these modifiable factors affect endothelial and astrocyte function. Studies on an aging population are necessary not only because it is the target population for ischemic disease, but also because such comparative age analyses have the potential to uncover new therapeutic targets. A good example of this strategy is the growth factor IGF-1, which is known to decrease with aging in virtually all mammals, was also found to be neuroprotective in stroke. In middle-aged female animals, the loss of IGF-1 appears to alter the neuroprotective capacity of estrogen (Selvamani and Sohrabji, 2010b) .
In view of the data that stroke severity is worse in older women, studies should include both males and females and the impact of hormone loss and exogenous hormone treatment should be carefully studied in an aging model. While sex differences affect functional capacity of support cells and sexually dimorphic responses have been reported for therapeutic interventions in stroke models, these differences need to be addressed in a more systematic manner. In this context, new advances for live imaging (Cordeau et al., 2008) and culturing of support cells (Foo et al., 2011) will be critical adjuncts for understanding how these cells contribute to or hinder neuronal survival and brain repair.
